{"id":40627,"title":"Robert F Kennedy Jr Sparks Vaccine Industry Turmoil","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2025-04-01T05:25:11+00:00","modified":"2025-04-01T05:25:11+00:00","canonical_url":"https://stockmark.it/robert-f-kennedy-jr-sparks-vaccine-industry-turmoil/","markdown_url":"https://stockmark.it/robert-f-kennedy-jr-sparks-vaccine-industry-turmoil.md","json_url":"https://stockmark.it/robert-f-kennedy-jr-sparks-vaccine-industry-turmoil.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical","Stockmarket"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.stockmark-it-66-1.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"Almost £8 billion has been erased from the value of the world’s largest pharmaceutical companies following the unexpected ousting of America’s leading vaccine authority by Robert F Kennedy Jr. Shares in Moderna, Pfizer, and GSK experienced significant declines, igniting fears of instability within the vaccine sector.\n\nInitial reports indicated that Moderna shares plummeted by as much as 13 percent during early trading in New York, while Pfizer saw a decrease of 1.5 percent. In the UK, AstraZeneca and GSK also faced losses of approximately 2 percent each. The collective sell-off resulted in a staggering near £8 billion wiped from the market.\n\nThis market reaction was primarily driven by apprehensions regarding Donald Trump’s impending tariffs, coupled with rising uncertainties following the resignation of Dr Peter Marks from the Food and Drug Administration (FDA). Dr Marks had previously challenged Mr Kennedy’s controversial stances on vaccine safety, highlighting a significant ideological rift within the administration.\n\nDr Marks articulated serious concerns in his resignation letter, stating that it had become evident that truth and transparency were no longer priorities for the secretary. His remarks underscored the perceived danger posed by undermining public confidence in vaccines, which have consistently met rigorous standards for quality and safety established over decades at the FDA.\n\nAnalysts are expressing cautious outlooks regarding the potential ramifications of Dr Marks’s departure on global vaccine manufacturers. As Matt Phipps, an analyst at William Blair, stated, uncertainty surrounding Dr Marks’ successor could create significant challenges for the industry, particularly if the new appointee aligns more closely with Secretary Kennedy’s views.\n\nThe FDA has yet to disclose who will succeed Dr Marks. The ongoing volatility in the stock market raises crucial questions about the future direction of vaccine policy in the U.S. and its implications for public health initiatives worldwide."}